ABS Investment Management’s Indivior Pharmaceuticals INDV Stock Holding History

ABS Investment Management’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$140K	Buy	+41	New	+$1.49K	0.09%	104

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABS Investment Management's INDV Position: Q2 2026 in Review

ABS Investment Management opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 41 shares worth $140K. The stake represents 0.09% of the portfolio and ranks #104 among its holdings.

315 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

ABS Investment Management held 41 shares of Indivior Pharmaceuticals worth $140K as of Q2 2026.
Indivior Pharmaceuticals was a new ABS Investment Management position in Q2 2026.
Indivior Pharmaceuticals made up 0.09% of ABS Investment Management's portfolio in Q2 2026, its #104 holding.
315 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on ABS Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.